Anbio Biotechnology (NNNN) Registration filing summary

Company overview and business model

• Focuses on in vitro diagnostics (IVD) products for personalized and decentralized healthcare, offering solutions for OTC, point-of-care, and laboratory settings.

• Product portfolio includes tests for infectious diseases, cancer, cardiovascular, endocrine, renal, pharmacogenomics, and diabetes, using established IVD technology platforms.

• Operates as a holding company with main operations in Europe via a BVI subsidiary; products are manufactured by third-party suppliers.

• All IVD products are CE marked under IVDD and ready for commercialization; expansion targets EU, APAC, Americas, and Africa.

• Revenue is primarily from rapid antigen tests for COVID-19 and respiratory diseases, with diversification into non-COVID products since 2023.

Financial performance and metrics

• Revenue for FY 2023 was $6.71M (down from $23.54M in 2022); net income was $2.25M (down from $10.01M in 2022).

• For the six months ended June 30, 2024, revenue was $5.85M (up from $3.06M in 2023); net income was $3.60M (up from $1.52M in 2023).

• Gross margin for FY 2023 was 50.1%; for the six months ended June 30, 2024, gross margin was 66.85%.

• As of June 30, 2024, cash and cash equivalents were $10.3M; working capital was $18.2M.

• Significant customer concentration: top four customers accounted for 83% of 2023 revenue; top three for 82% of H1 2024 revenue.

Use of proceeds and capital allocation

• Net proceeds of ~$7.0M (assuming $5.00/share IPO price) to be used 35% for sales/distribution expansion, 20% for R&D, and 45% for working capital/general corporate purposes.

• Proceeds will not be used for regulatory filings; existing cash reserves will cover those expenses.